RxDoctor Payments DataLook up a doctor →

Kawsar Talaat, MD

Infectious Disease · Baltimore, MDNPI 1588858740

Payments from drug & device makers

$4,178,055in general payments, 2019–2025

Across 351 payments — averaging $11,903 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3.5M
  • Sanofi Pasteur Inc.$369K
  • Valneva Austria GmbH$228K
  • Merck$32K
  • Sanofi US Services Inc.$27K
  • Modernatx, Inc.$14K
  • plus $45 from 1 others
$15,100in research payments, 2019–2025

Across 10 payments — averaging $1510.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$15K

What the payments were for

  • Consulting fees$45,673100%
  • Food & beverage$450%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer203$3,508,339
Sanofi Pasteur Inc.62$369,393
Valneva Austria GmbH2$227,737
Merck45$31,988
Sanofi US Services Inc.32$26,869
Modernatx, Inc.6$13,685
Seqirus USA Inc1$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,178,055 in reported general payments places this provider in the 95th percentile of 289 infectious disease providers in Maryland.

See all infectious disease providers in Maryland

Medicare billing

Part B allowed, 2024
$5,404
Medicare patients
23
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →